rubidium-82(1+);chloride

• 分子结构分类: 无机化合物 - 混合金属/非金属化合物 - 碱金属盐
• 英文名称: rubidium-82(1+);chloride
• 化学式: ClRb
• 分子量: 117.37
• InChiKey: FGDZQCVHDSGLHJ-RYDPDVNUSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -5.99
• 重原子数：
  2
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

ADMET

毒理性

• 药物性肝损伤

化合物：氯化铷 RB-82

Compound:rubidium chloride rb-82

来源:Drug Induced Liver Injury Rank (DILIrank) Dataset

毒理性

• 药物性肝损伤

DILI 注解：无 DILI（药物性肝损伤）担忧

DILI Annotation:No-DILI-Concern

来源:Drug Induced Liver Injury Rank (DILIrank) Dataset

毒理性

• 药物性肝损伤

标签部分：没有匹配项

Label Section:No match

来源:Drug Induced Liver Injury Rank (DILIrank) Dataset

毒理性

• 药物性肝损伤

参考文献：M Chen, V Vijay, Q Shi, Z Liu, H Fang, W Tong. 用于研究药物诱导肝损伤的FDA批准药物标签，药物发现今天，16(15-16):697-703, 2011. PMID:21624500 DOI:10.1016/j.drudis.2011.05.007 M Chen, A Suzuki, S Thakkar, K Yu, C Hu, W Tong. DILIrank：按在人类中发展药物诱导肝损伤风险排名的最大参考药物清单。药物发现今天 2016, 21(4): 648-653. PMID:26948801 DOI:10.1016/j.drudis.2016.02.015

References:M Chen, V Vijay, Q Shi, Z Liu, H Fang, W Tong. FDA-Approved Drug Labeling for the Study of Drug-Induced Liver Injury, Drug Discovery Today, 16(15-16):697-703, 2011. PMID:21624500 DOI:10.1016/j.drudis.2011.05.007 M Chen, A Suzuki, S Thakkar, K Yu, C Hu, W Tong. DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov Today 2016, 21(4): 648-653. PMID:26948801 DOI:10.1016/j.drudis.2016.02.015

来源:Drug Induced Liver Injury Rank (DILIrank) Dataset

毒理性

• 在妊娠和哺乳期间的影响

◉ 母乳喂养期间使用概述：本记录中的信息是指将氯化铷Rb 82用作诊断剂。目前没有关于在母乳喂养期间使用氯化铷Rb 82的信息。制造商建议在给予氯化铷Rb 82的诊断剂量后暂停哺乳1小时。这段时间超过了放射性同位素的10个半衰期，因此如果遵循这一指导原则，哺乳婴儿不应暴露于辐射。母亲可以在给予放射性药物之前哺乳。如果母亲在检查前已经挤出并保存了乳汁，她可以在哺乳中断期间喂给婴儿。其他权威机构表示，没有必要停止哺乳。 ◉ 对哺乳婴儿的影响：截至修订日期，没有找到相关的已发布信息。 ◉ 对泌乳和母乳的影响：截至修订日期，没有找到相关的已发布信息。

◉ Summary of Use during Lactation:Information in this record refers to the use of rubidium chloride Rb 82 as a diagnostic agent. No information is available on the use of rubidium chloride Rb 82 during breastfeeding. The manufacturer recommends withholding breastfeeding for 1 hour after a diagnostic dose of rubidium chloride Rb 82.This length of time is greater than 10 half-lives of the radioisotope, so the nursing infant should not be exposed to radiation if this guideline is followed. The mother can nurse just before administration of the radiopharmaceutical. If the mother has expressed and saved milk prior to the examination, she can feed it to the infant during the period of nursing interruption. Other authorities state that no discontinuation of breastfeeding is necessary. ◉ Effects in Breastfed Infants:Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.

来源:Drugs and Lactation Database (LactMed)